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Background: Inferior vena cava filters (IVCFs) can prevent pulmonary embolism (PE); however, indications for use vary.
The Eastern Association for the Surgery of Trauma (EAST) 2002 guidelines suggest prophylactic IVCF use in high-risk
patients, but the American College of Chest Physicians (ACCP) 2008 guidelines do not. This analysis compares
cost-effectiveness of prophylactic vs therapeutic retrievable IVCF placement in high-risk trauma patients.
Methods: Markov modeling was used to determine incremental cost-effectiveness of these guidelines in dollars per
quality-adjusted life-years (QALYs) during hospitalization and long-term follow-up. Our population was 46-year-old
trauma patients at high risk for venous thromboembolism (VTE) by EAST criteria to whom either the EAST
(prophylactic IVCF) or ACCP (no prophylactic IVCF) guidelines were applied. The analysis assumed the societal
perspective over a lifetime. For base case and sensitivity analyses, probabilities and utilities were obtained from published
literature and costs calculated from Centers for Medicare & Medicaid Services fee schedules, the Healthcare Cost &
Utilization Project database, and Red Book wholesale drug prices for 2007. For data unavailable from the literature,
similarities to other populations were used to make assumptions.
Results: In base case analysis, prophylactic IVCFs were more costly ($37,700 vs $37,300) and less effective (by 0.139
QALYs) than therapeutic IVCFs. In sensitivity analysis, the EAST strategy of prophylactic filter placement would become
the preferred strategy in individuals never having a filter, with either an annual probability of VTE of >9.6% (base case,
5.9%), or a very high annual probability of anticoagulation complications of>24.3% (base case, 2.5%). The EAST strategy
would also be favored if the annual probability of venous insufficiency was<7.69% (base case, 13.9%) after filter removal
or <1.90% with a retained filter (base case, 14.1%). In initial hospitalization only, EAST guidelines were more costly by
$2988 and slightly more effective by .0008 QALY, resulting in an incremental cost-effectiveness ratio of $383,638/
QALY.
Conclusions: Analysis suggests prophylactic IVC filters are not cost-effective in high-risk trauma patients. The magnitude
of this result is primarily dependent on probabilities of long-term sequelae (venous thromboembolism, bleeding
complications). Even in the initial hospitalization, however, prophylactic IVCF costs for the additional quality-adjusted
life years gained did not justify use. ( J Vasc Surg 2010;52:1537-45.)Prevention of venous thromboembolism (VTE) can be
a difficult and complex issue in the trauma patient. Fatal
pulmonary embolism (PE) may occur without warning,
despite noninvasive venous screening and lack of clinical
evidence of deep venous thrombosis (DVT). Immobiliza-
tion devices may preclude mechanical prophylaxis, and
ongoing bleeding or risk of bleeding may make anticoagu-
lation contraindicated, at least early in the period, in up to
14% of trauma patients.1 Because of these factors, trauma
surgeons increasingly have used inferior vena caval (IVC)
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doi:10.1016/j.jvs.2010.06.152interruption as a form of PE prophylaxis. Patients at partic-
ularly high risk for PE immediately after a traumatic injury
include those with spinal cord injury, pelvic fracture, lower
extremity fracture, venous repair, injury severity score (ISS)
9 or 15, history of thromboembolism, coma (Glasgow
Coma Scale [GCS] 8), or age 45 years with enforced
bed rest for 3 days.1-4
Two sets of guidelines provide conflicting recommen-
dations for placement of IVC filters (IVCFs). The Ameri-
can College of Chest Physicians (ACCP) 2008 guidelines
suggest IVCF insertion in patients with proven proximal
DVT or PE who are unable to receive anticoagulation due
to risk of bleeding, with anticoagulation added once the
risk of bleeding resolves,5 but recommend against use of an
IVCF as thromboprophylaxis in trauma patients.6
The Eastern Association for the Surgery of Trauma
(EAST) 2002 guidelines, however, provide a level III rec-
ommendation that insertion of a prophylactic IVCF should
be considered in very-high-risk trauma patients.7 These are
patients unable to receive anticoagulation because of in-
creased bleeding risk coupled with prolonged immobiliza-
tion. Injuries fitting this pattern include severe closed head
injury with GCS 8, incomplete spinal cord injury with
paraplegia or quadriplegia, complex pelvic fractures with
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tures.7
Given these conflicting recommendations regarding
placement of IVCFs, we can examine the clinical and eco-
nomic implications of each placement strategy and salient
factors influencing the results by using Markov modeling.
Here we examined the cost-effectiveness of prophylactic
indications for IVCFs according to the EAST criteria vs
traditional (therapeutic) indications for IVCFs according to
AACP 2008 guidelines among high-risk trauma patients
with acute contraindications to anticoagulation.
METHODS
Target population. Our hypothetic cohort was 46
years old and met EAST definitions for high-risk trauma
patients: those who are unable to receive anticoagulation
due to high risk for bleeding complications for 5 to 10 days
after injury, including intracranial hemorrhage, ocular in-
jury with associated hemorrhage, solid intra-abdominal
organ injury, and/or pelvic or retroperitoneal hematoma
requiring transfusion, with one or more of closed head
injury with GCS 8, spinal cord injury with paraplegia or
quadriplegia, and complex pelvic fractures with associated
long-bone fractures or multiple long-bone fractures.7,8
Model description. A Markov model with a 1-day
cycle length was used to simulate hospital stay as well as
long-term (post-discharge) complications over the lifetime
of the patient. The target population began in an initial
high-risk state for VTE while unable to be anticoagulated,
and the model branched for either the EAST or ACCP
guidelines for IVCF placement to be applied. A simplified
schematic depiction of the inpatient portion of the model is
shown in Fig 1, with the full tree structure available in
Appendix A (online only).
In the EAST branch, prophylactic filters were placed at
a daily probability based on the literature’s average time to
filter placement. During the inpatient stay, patients en-
countered daily probabilities of dying and of becoming
symptomatic from a suspected DVT or PE (represented by
the VTE state in the figure), leading to filter placement in
the following cycle. Based on tree structure, all filters were
placed after hospital day 1. The cohort cycled through the
model, with or without a filter, either remaining asymp-
Fig 1. Conceptual diagram of states modeled. Tree structure con-
tains additional complexity for prophylactic and therapeutic anticoag-
ulation as well as filter status (with/without during inpatient course
and as an outpatient–never having a filter, successfully removed filter,
or retained filter). VTE, Venous thromboembolism.tomatic or becoming symptomatic with a suspected PE orDVT. Evaluation for suspected PE or DVT had a probabil-
ity of positive imaging, which would result in anticoagula-
tion (if not contraindicated), observation (if filter already
placed and anticoagulation contraindicated), or placement
of a filter (if one was not already inserted and anticoagula-
tion remained contraindicated).
As implemented, the ACCP strategy is identical to the
EAST strategy except for having zero probability of pro-
phylactic IVCF placement, such that IVCFs were placed
only with a positive imaging study of PE or DVT when
anticoagulation was contraindicated. Because the ACCP
guidelines recommend instituting anticoagulation therapy
once bleeding risk resolves,5,6 after a threshold number of
days, the cohort could cycle through states in which indi-
viduals are able to receive prophylactic or therapeutic anti-
coagulation. While receiving prophylactic or therapeutic
anticoagulation, individuals with and without filters again
had probabilities of symptoms developing that required
evaluation by imaging, or, if remaining asymptomatic, had
a probability of hospital discharge.
All patients with filters placed had a filter removal
attempt before discharge. The daily probability of dis-
charge, reflecting duration of hospital stay, was assumed to
be primarily related to the injury mechanism and ability to
safely anticoagulate the patient, rather than factors related
to filter status; however, in the context of the model, one
extra day of hospitalization was required to implant the
filter, and one extra day was required for an attempt at filter
retrieval.
After discharge (not shown in Fig 1), individuals who
never had a filter placed, had a successfully removed filter,
or a retained filter, cycled through their own set of outpa-
tient states in which daily age-specific mortality risks based
on the 2004 U.S. life tables were encountered,9 modified
by a slight survival advantage for those with retained filters.
If surviving, an individual faced a daily probability of devel-
oping complications specific to never, currently, or for-
merly having had a filter.
The initial mechanisms of injury putting individuals at
very-high risk for VTE by EAST criteria7 were used to
assume that all patients might continue to have sufficient
mobility limitation to warrant an average of a 6-month
course of anticoagulation after discharge. For individuals of
each filter status, long-term complications encountered
daily included VTE resulting in hospitalization for PE or
DVT; if no VTE occurred within a cycle, a probability of a
hemorrhage occurring during a 6-month post-hospital
course of anticoagulation, as well as a probability of having
venous insufficiency, were considered.
Perspective, boundaries, time horizon. The societal
perspective was used and included both direct and indirect
costs, including lost wages in the long-term, but not acute,
hospitalization states. The time horizon was the lifetime of
the cohort, confined to a maximum age of 100 years.
Probability data. Probability data were calculated
from rates in the published vascular surgery and trauma
literature. Because our modeling used a 1-day cycle length,
probabilities and rates from the literature were converted to
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Inc, Williamstown, Mass) commands ProbtoRate and
RatetoProb to convert probabilities to rates and rates to
probabilities over the appropriate time horizons which
reflect the relation that p  1-e–rt, where p represents
probability, r, rate, and t, time. Using this relation, we also
used median time to event data to determine daily proba-
bilities. Table I reports detailed probabilities, parameters,
and references.
Costs and utilities. Costs were calculated from Cen-
ters for Medicare & Medicaid Services (CMS) fee sched-
ules,41-43 the Healthcare Cost & Utilization Project
(HCUP) database,40 and Red Book wholesale drug prices
for 200744 (Table II). For data unavailable from the liter-
ature, assumptions were set forth based on similarities to
other populations. Utilities, ranging from 0 (death) to 1
(perfect health), weight the time spent in a health state by
the desirability of the health state to determine quality-
adjusted life-years (QALY). Utilities were obtained from
the published literature and the New England Medical
Center Utility Search Database48 (Appendix B, online
only). Future costs and utilities were discounted at 3%.
Analysis. Base case cost-effectiveness analysis, deter-
mining the incremental cost-effectiveness ratio (ICER) of
the EAST guidelines relative to the ACCP guidelines, was
performed using TreeAge Pro 2008 software. One-way
sensitivity analyses were also performed to test how robust
the base case results were and determine influential vari-
ables. A conventional threshold for cost-effectiveness is an
ICER of $50,000/QALY. We used the sensitivity analysis
to determine which variables would change the preferred
strategy from the base case, and at which threshold. The
EAST strategy was considered the preferred filter place-
ment strategy if one of the following occurred:
● if the ICER of the EAST strategy relative to the ACCP
strategy was $50,000/QALY;
● if the EAST strategy was less effective and less costly
than the ACCP strategy, while the ICER of the ACCP
strategy was $50,000/QALY; or
● if the ACCP strategy was dominated by the EAST
strategy being less costly and more effective.
The ACCP strategy was preferable in the converse of the
above cases.
RESULTS
Base case analysis. In base case analysis over the life-
time of a patient, the prophylactic IVCF (EAST) strategy
was not cost-effective, being both more costly ($37,700 vs
$37,300) and less effective by 0.139 QALYs (15.473 vs
15.612) than therapeutic IVCF placement.
Sensitivity analysis. In one-way sensitivity analyses,
the variables causing the biggest change in ICER magni-
tude were the probabilities of VTE after successful IVCF
retrieval, and VTE with a retained IVCF. These were
followed by the probabilities of anticoagulation-related
bleeding events in individuals never having a filter or with a
retained filter. The probability of inpatient discharge forthose with filters placed as well as the probability of VTE in
individuals never having a filter placed also caused notable
variation in the magnitude of the ICER (Fig 2).
Although the above variables had a significant effect on
the magnitude of the ICER, with the exception of the
probability of inpatient discharge and probability of VTE in
individuals never having a filter placed, the ACCP strategy
of filter placement would remain preferred over the full
range of clinically reasonable probabilities. The EAST strat-
egy would be cost-effective, with an ICER of $50,000/
QALY at the probabilities of inpatient death or hospital
discharge as listed in Table III. These sensitivity analysis
results demonstrate that the EAST strategy of prophylactic
filter placement would become cost-effective as the proba-
bility of inpatient death in patients without a filter increases,
the probability of inpatient death in patients with a filter
decreases, and as hospital stays become longer for those
without a filter and shorter for those with a filter.
Among the long-term probabilities of influence in the
model, several could affect the preferred choice of strategy.
In individuals never having a filter, an annual probability of
VTE 9.6% (base case, 5.9%) would make the EAST
strategy preferred, as would a very high annual probability
of anticoagulation complications of 24.3% (base case,
2.5%). The EAST strategy would be favored among those
with successfully removed filters if the annual probability of
venous insufficiency were 7.69% (base case, 13.9%) or
1.90% among those with retained filters (base case,
14.1%).
Owing to the influence of the probabilities of long-
term VTE and other complications on the model, we also
examined the cost-effectiveness of the EAST and ACCP
guidelines over the more limited time horizon of only the
hospitalization. In this scenario, the EAST guidelines were
more costly ($16,518 vs $13,530) and more effective (by
0.007789 QALYs); however, the ICER of $383,638/
QALY greatly exceeded the commonly accepted threshold
for practical cost-effectiveness of $50,000/QALY. By our
above definitions, the ACCP guidelines would remain the
preferred choice.
It is also important to note several structural assump-
tions of our model that were shown not to affect the results
in sensitivity analyses. In particular, the time to prophylactic
filter placement may vary significantly by institution; how-
ever, even if all in the EAST cohort were required to receive
a filter after day 1, the EAST strategy remains dominated,
with a cost of $37,800 and effectiveness of 15.499 QALYs,
whereas the ACCP strategy cost $37,300 with 15.612
QALYs.
Similarly, our assumption of 6 months of anticoagula-
tion therapy after the initial hospitalization for likely mo-
bility limitation may vary by institution. We explored the
role of extending the duration of anticoagulation by in-
creasing the costs of anticoagulation (medication and sur-
veillance testing) and increasing the duration of disutility
from use of anticoagulation. Assuming these costs scale
linearly, even increasing the duration of outpatient antico-
agulation out to 5 years would not affect the model’s
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Parameter Base case (%) Range (%) References
Inpatient probabilities
Weekly probability of death
In initial high risk state 0.24 0.15-1.47 10-12
Given no filter and receiving prophylactic
anticoagulation
1.47 0.00-5.00 11
Given no filter and receiving therapeutic
anticoagulation
0.06 0.06-1.47 11,13
Given filter placed 0.84 0.0-5.00 14
With a filter while ineligible for anticoagulation 0.07 0.06-1.32 15-17
With a filter receiving prophylactic anticoagulation 1.47 0.0-5.00 11
With a filter receiving therapeutic anticoagulation 1.47 0.0-5.00 Assumed same as prophylactic
anticoagulation
Weekly probability of inpatient symptoms
In initial high risk state 2.41 0.0005-3.24 1,18,19
Given no filter and receiving prophylactic
anticoagulation
1.58 0.16-25.23 11,18,20
During filter placement with complications 1.17 0.01-5.67 21-23
At time of uncomplicated filter placement 0.17 0.007-1.17 Assumed same as with filter while
ineligible for anticoagulation
With a filter while ineligible for anticoagulation 0.17 0.007-1.17 23-25
With a filter, receiving prophylactic
anticoagulation
0.64 0.64-2.65 11
With a filter, receiving therapeutic anticoagulation 0.64 0.64-2.65 Assumed same as prophylactic
anticoagulation
Daily probability of filter placement given no
symptoms
15.9 15.9-20.6 26,27
Daily probability eligible for prophylactic
anticoagulation
0 if days  threshold
1 if days  threshold
N/A
Threshold number of days for beginning
anticoagulation
5 0-14 Assumption
Daily probability of discharge with filter 4.8 3.6-7.4 26,28,29
Daily probability of hospital discharge given no filter 5.6 4.0-9.4 Computed from probability of
discharge with filter
Probability of positive imaging study in suspected
PE/DVT
96.0 96.0-100.0 30
Probability of a false negative on imaging study 9.6 0.0-9.6 30
Probability of filter placement complication 3.2 1.6-16.7 31-33
Probability of successful filter removal 76.9 34.8-100 16,23,34
Outpatient probabilities
Annual condition-specific decrease in mortality
related to filter remaining in long-term [for
those with filter]
0.7 0.005-0.7 Calculated from difference in
death rates35
Annual probability of outpatient VTE
Among those never having a filter 5.9 0.6-6.4 11,12, 36
Among those with successfully removed filters 4.6 0.6-42.4 23
Among those with retained filters 6.1 0.4-70.7 14,25,32,35,37,38
Conditional probability of PE given a VTE
outpatient
Among those never having a filter 33.7 7.5-83.4 11,12,36
Among those with successfully removed filters 15.4 1.1-24.8 23
Among those with retained filters 12.6 0.5-15.4 14,25, 32,35,37,38
Annual probability of bleed during 6 months of
anticoagulation
Among those never having a filter 2.5 2.1-60.4 11,33
Among those with successfully removed filters 2.5 2.1-60.4 Assumed same as never having a
filter
Among those with retained filters 2.1 2.1-60.4 11
Annual probability of venous insufficiency
Among those never having a filter 13.9 0.1-14.1 35,37
Among those with a successfully removed filter 13.9 0.1-14.1 Assumed same as never having a
filter
Among those with retained filters 14.1 0.1-14.1 32,35,37
Annual probability of ulceration given chronic 4.5 ... 39
venous insufficiency
tinal; I
embol
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for 15.431 QALYs) remaining dominated by the ACCP
guidelines ($39,500 for 15.57 QALYs). Our proposed
regimen had considered maintaining an international nor-
malized ratio (INR) of 2.0 to 3.0 during anticoagulation
because the probability of major bleeding events was de-
rived from the Prevention du Risque d’Embolie Pulmon-
aire par Interruption Cave (PREPIC) trial,35 which had
maintained this INR range; however, a lower-dose regimen
could be considered and would primarily affect this proba-
bility. Considering the case of no warfarin use, the preferred
Table 1. Continued
Parameter B
Other parameters
Time away from work during the 6 months of
anticoagulation
2 hour
Time away from work per year for venous
insufficiency
1 hour
Median length of stay in hospitalization for PE 5.0 da
Median length of stay in hospitalization for DVT 4.0 da
Median length of stay in hospitalization for GI bleed 3.0 da
DRG,Diagnosis RelatedGroup;DVT, deep vein thrombosis;GI, gastrointes
venous thromboembolism.
Table II. Costs
Parameter Baseline ($) Ran
Baseline cost of hospitalization 12,702.80 6979.00
Daily cost of prophylactic anticoagulation 17.115 0.78
Cost of initial day therapeutic
anticoagulation
169.14 4.89
Cost of subsequent days of therapeutic
anticoagulation
143.51 7.10
Cost of CT thorax 230.56 53.53
Cost of filter placement 1417.77 1110.08
Cost of filter placement complication 0 0
Cost of filter removal 1612.08 1200.16
Total cost of anticoagulation for 6
months
219.14 106.15
Cost of hospitalization for PE 11,004.77 7922.36
Cost of hospitalization for DVT 8300.91 5133.36
Cost of hospitalization for GI bleed 6118.01 4489.66
Daily cost of venous insufficiency 0.87 0.29
Hourly private nonfarm worker wage 17.50
Cost of death 5000.00
CT, Computed tomography; DVT, deep venous thrombosis; EGD, esopha
International Classification of Disease; GI, gastrointestinal; PE, pulmonaryoutcome remained the ACCP strategy.The risk of VTE in the trauma patient increases with
age, but a numeric cutoff for the age at which the risk of
VTE significantly increases has not been firmly established
in epidemiologic analyses.7 The base case of age 46 was
chosen to maintain some consistency with the cost-benefit
analysis by Brasel et al8; however, in one-way sensitivity
analyses varying the starting age, the ACCP guidelines
remained the favored strategy throughout. For an 18-year-
old, the EAST strategy would cost $43,838 with an effec-
tiveness of 21.42 QALYs, whereas the ACCP guidelines
would cost $44,275 with an effectiveness of 21.61 QALYs.
se (%) Range (%) References
... Assumption
... Assumption
5.0-6.3 40(Upper age ranges only, ICD-9
code 415.19)
4.0-5.3 40(Upper age ranges only, ICD-9
code 453.41)
2.0-3.5 40(Upper age ranges only, DRG
175)
CD, International Classification of Disease; PE, pulmonary embolism;VTE,
) Reference Description/Code(s)
53.00 40 ICD-9 codes 344.1, 344.00, 432.9,
808.43
7 44 Average prophylactic cost of Lovenox
or heparin use
.64 42,44 Heparin bolus, ½ day infusion, 1 day of
testing PT/PTT q4hr, warfarin
.16 42,44 1 day infusion, q24hr testing PT/PTT,
warfarin
.60 41 HCPC 71260
7.63 41 HCPC 36010, 37620, 75940-26
7.77 Assumption Range: none to cost of placing filter
again
5.42 41 HCPC 37203,75961-26
.99 44 9 venipunctures 9 PT checks, 180 days
of warfarin 5 mg daily
83.82 40,41 Evaluation and management, CT, PE
hospitalization, anticoagulation
0.61 40,41 Evaluation and management, CT, DVT
hospitalization, anticoagulation
3.17 40,41 Evaluation and management, EGD, GI
bleed hospitalization, colonoscopy
39,41,43,45 2 new sets of compression stockings per
year. 1 duplex every 5 years, annual
office visit, annual cost of ulceration
46
Assumption 47
troduodenoscopy; HCPC, Healthcare Common Procedure Coding; ICD,
ism; PT, prothrombin time; PTT, partial thromboplastin time.ase ca
s
ys
ys
ysge ($
-23,6
-36.3
-439
-513
-494
-189
-141
-229
-465
-11,6
-890
-649
-2.02
...
...
gogasThe EAST strategy at this age is less costly and less effective,
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in costs narrows with age, and by age 35, the EAST strategy
is dominated, being more costly and remaining less effec-
tive: $30,621 yielding 18.31 QALYs for EAST vs $40,610
and 18.47 QALYs for ACCP. At age 35, the EAST
strategy remains dominated by the ACCP strategy. Consid-
ering only the duration of the initial hospitalization, the
result is unaffected by the starting age because such a short
time period is considered in the analysis, with EAST costing
$16,518 and yielding 0.03 QALYs, whereas the ACCP
strategy is less costly and less effective at $13,530 yielding
0.02 QALYs, giving the EAST strategy an ICER of
Fig 2. A tornado diagram shows themagnitude of the in
literature values for the six variables displaying the great
ACCP, American College of Chest Physicians; EAST, Ea
tinal; VTE, venous thromboembolism.
Table III. Sensitivity analysis
Parameter
Base
case (%)
Probability at which
ICER is $50,000/
QALY (%)
Weekly probability of death
In initial high-risk state 0.24 22.9
Given no filter and receiving
prophylactic anticoagulation 1.47 1.9
Given no filter and receiving
therapeutic anticoagulation 0.06 12.5
With a filter receiving
prophylactic anticoagulation 1.47 1.1
Daily probability of discharge with
filter 4.8 6.2
Daily probability of hospital
discharge given no filter 5.6 4.4
ICER, Incremental cost-effectiveness ratio; QALY, quality-adjusted life-
years.$383,638.Although the analysis assumed outpatient age-specific
mortality risks equivalent to the general U.S. population
life tables (modified by a slight survival advantage for
retained filters as derived from the PREPIC results35),
trauma patients may have decreased life expectancy. Con-
sidering cases as extreme as adding a 50% annual probability
of dying did not affect the preferred result, though the
utilities of both strategies decreased significantly due to the
decrease in life span.
DISCUSSION
Prior examinations of cost-effectiveness related to
IVCFs have been limited in applicability to the trauma
population,49 in scope or perspective,50-52 or in providing
only a cost-benefit analysis.8 The cost-effectiveness results
presented suggest that prophylactic placement of IVCFs in
high-risk trauma patients is not cost-effective from a soci-
etal perspective. These results are theoretic and constrained
by both the assumptions and structure of the model used to
derive them and the quality and extent of evidence in the
literature, especially regarding long-term complications.
Within these constraints, however, we found the ACCP
strategy of therapeutic placement of IVCF in high-risk
trauma patients is most appropriate.
The importance of our analysis is that it highlights the
conflict between these practice guidelines and should serve
as a springboard for further comparative research, both
clinical and cost-effective. Although this project models a
theoretic cohort and is not intended for individual clinical
decision making, it illustrates the costs to society and
the importance of the probabilities of complications to the
ental cost-effectiveness ratio over the range of reasonable
riation. The vertical yellow line represents the base case.
Association for the Surgery of Trauma; GI, gastrointes-crem
est va
sternindividual in which the consequences may outweigh the
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aspect of this type of modeling is its ability to identify
thresholds of variables that could sway decisions. The
thresholds from sensitivity analyses can be viewed either as
confidence limits on the results where the literature is not
strong or, potentially, as goals for device refinement, qual-
ity improvement, or risk stratification in order for a given
filter utilization strategy to become cost-effective.
The aim of our model was to adequately characterize
both inpatient and outpatient long-term complications
while avoiding unnecessary complexity. For example, the
ACCP recommends ultrasound screening in patients who
are at high risk for VTE and have received suboptimal or no
thromboprophylaxis,6 but these schedules are not stan-
dardized. From a modeling perspective, it would be diffi-
cult to account for the proportion of positive asymptomatic
examinations and the associated imaging or therapeutic
costs incurred. In addition, the ACCP recommends against
ultrasound screening for asymptomatic DVT in trauma
patients as a whole.6 We thus omitted ultrasound screening
from our model because it seemed clinically reasonable.
Similarly, for modeling purposes, suspected PE and
DVT were lumped together without consideration of pro-
gression of DVT to PE because confirmed VTE is an AACP
indication for filter use. Although imaging evaluation for
DVT might be reasonably limited to ultrasound, because
our model considered symptomatic DVT and PE, cost of a
computed tomography thorax scan represented a reason-
able estimate of an imaging workup that might be under-
taken. Use and costs of pneumatic compression devices
were considered to be a component of the inpatient hospi-
talization. For outpatients, costs and utilities of anticoagu-
lation complications were primarily limited to evaluation
and management of nonfatal gastrointestinal bleeding.
Probabilities were drawn from published literature to
make the model as applicable to clinical practice as possible.
For many probabilities, however, there was no perfect
source of information. For example, the probability of
death without an IVCF when anticoagulation is contrain-
dicated was drawn from historic controls in which it is not
documented how many trauma patients might have re-
ceived some anticoagulation.10
Similarly, there is a relative paucity of literature regard-
ing long-term consequences of retrievable IVCFs because
the Food and Drug Administration first granted approval
for use in July 2003. This restricted our ability to model
long-term complications of a retained IVCF. We therefore
assumed that these individuals had probabilities equivalent
to the literature for permanent IVCFs, and that those with
successfully removed filters were similar to individuals who
had never had a filter. We did not restrict our filter data to
one brand of IVCF in order to make the results broadly
applicable, although within the literature, different makes
of IVCF have different complication rates.
For retained IVCFs, most of the probabilities were
determined from the 8-year cumulative results of the
PREPIC study, the only long-term randomized study of
filter placement in the prevention of pulmonary embo-lism.11,35 However, the PREPIC participants differed from
our cohort in several regards: they were not required to be
trauma patients, only considered to be at high risk for PE
and with evidence of an acute proximal DVT by venogra-
phy with or without PE, and those with contraindications
to anticoagulation were excluded. All patients in the
PREPIC trial also received vitamin K antagonists for at least
3 months for a target INR of 2.0 to 3.0, although 35% of
patients received the vitamin K antagonists during all 8
years of follow-up or until their death. Our model stipu-
lated 6 months of warfarin therapy after hospital discharge
for all individuals on the basis of the severity of the injuries
classifying them at high risk by EAST criteria, which would
lead to continued reductions in mobility in the initial
months after discharge.
A filter removal attempt was required within the struc-
ture of the model before discharge for any individual in
whom a filter had been placed. The variable of success in
this attempt in the model accounts for both the low rate of
IVCF retrieval attempts in clinical practice as well as at-
tempted but unsuccessful retrievals. Although this model-
ing strategy leaves a portion of each cohort with retained
filters, it also may overcharge for filter removal. A review of
the one-way sensitivity analysis indicates that this overesti-
mation likely did not significantly alter the results, because
the cost of filter removal was the 12th most important
variable in the model, varying the ICER only $7515/
QALY over its range.
Finally, after hospital discharge, patients were consid-
ered to have an age-adjusted mortality equivalent to that of
the general population. A slight survival advantage (for
PE-specific mortality) was given to those with retained
filters based on the difference in death rates from the
PREPIC study. However, we are aware that with the older
population and increased number of cancer patients in the
PREPIC study, this was another area in which assumptions
were made to account for imperfect data sources. Sensitiv-
ity analysis of the survival advantage suggests a minimal
effect on the outcome, varying the ICER by only $30/
QALY over its range.
CONCLUSIONS
Our analysis suggests prophylactic IVCFs are not cost-
effective. This result is influenced by probabilities of long-
term sequelae (VTE, bleeding complications) that are
poorly characterized in the literature due to the recent
advent of retrievable filters and lack of long-term follow-up
in patients with retained and removed filters. Consistent
with the need to appropriately risk-stratify a potential re-
cipient of a prophylactic IVCF, we found the EAST strategy
could become preferred if the probability of inpatient death
or longer hospital stays in those without a filter was suffi-
ciently high, or the probability of these same events in those
with a filter was sufficiently low.
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